SIA
TSVT

SkyView Investment Advisors’s 2seventy bio TSVT Stock Holding History

SkyView Investment Advisors’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,500
Closed -$59K – 345
2024
Q3 		$59K Hold
12,500
– – 0.01% 245
2024
Q2 		$48K Buy
12,500
+2,500
+25% +$11.3K 0.01% 285
2024
Q1 		$54K Buy
+10,000
New +$47K 0.01% 265

Other funds holding TSVT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

SkyView Investment Advisors's TSVT Position: Q4 2024 in Review

SkyView Investment Advisors sold out of 2seventy bio (TSVT) in Q4 2024, closing a stake of 12,500 shares — an estimated $59K sold.

SkyView Investment Advisors first reported a position in TSVT in Q1 2024 and held it in 3 quarters. The position peaked at $59K in Q3 2024. 116 funds tracked by Wall St. Rank hold TSVT as of Q4 2024.

  • SkyView Investment Advisors reported no remaining 2seventy bio position as of Q4 2024 after selling out during the quarter.
  • SkyView Investment Advisors sold 12,500 2seventy bio shares in Q4 2024, an estimated $59K.
  • SkyView Investment Advisors first reported a position in 2seventy bio in Q1 2024 and held it in 3 quarters.
  • SkyView Investment Advisors's 2seventy bio position peaked at $59K in Q3 2024.
  • 116 funds tracked by Wall St. Rank held 2seventy bio as of Q4 2024.

Based on SkyView Investment Advisors's 13F filing for Q4 2024, filed 2 Jun 2025.